JORGE E CORTES to Diarrhea
This is a "connection" page, showing publications JORGE E CORTES has written about Diarrhea.
Connection Strength
0.289
-
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol. 2009 Oct 01; 27(28):4754-9.
Score: 0.064
-
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer. 2007 Sep 15; 110(6):1295-302.
Score: 0.056
-
Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia. Cancer Med. 2023 09; 12(17):17981-17992.
Score: 0.042
-
Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer. 2018 02 01; 124(3):587-595.
Score: 0.028
-
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015 Sep; 90(9):755-68.
Score: 0.024
-
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014 Oct; 89(10):947-53.
Score: 0.023
-
Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma. 2010 Feb; 51(2):269-74.
Score: 0.017
-
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007 Jan 15; 109(2):248-55.
Score: 0.013
-
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24.
Score: 0.012
-
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica. 2002 Aug; 87(8):804-7.
Score: 0.010